MedTrace Logo

A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors

NCT03815084 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-01-30

No results posted yet for this study

Summary

clinical study on the safety and efficacy of PD1 combined with dc-Nk in the treatment of solid tumors

Conditions

Interventions

DRUG

pd-1 and DC-NK cells

total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .

Sponsors & Collaborators

  • The First People's Hospital of Yunan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital

    collaborator UNKNOWN

  • Henan Provincial People's Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Allife Medical Science and Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-02-01
Completion
2021-02-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03815084 on ClinicalTrials.gov